DailyIQ
Last updatedUpdating…

CNC·Centene Corporation

$68.86
+1.84 (+2.75%)
Pre-Market
High
$69.25
Open
$69.20
Market Cap
32.91B
52W High
$70.04
Low
$68.83
P. Close
$68.86
P/E
-
52W Low
$31.50
Fwd P/E
12.88
DailyIQ Est.
$72.65
Inst. Ownership
51.8%
Short Interest
2.21%
Days to Cover
2.0
Technical Score (1D)
92
BULLISH
News Sentiment
63
BULLISH
On Oct 13, Centene Corporation announced a National Performance‑Based Gold Card Program that will simplify prior authorization for more than 160,000 providers and is scheduled to launch in November 2026. The same day the company confirmed its plan to redeem the remaining $568.66 million of 4.25 % Notes due 2027, which was expected to strengthen its balance sheet. Centene also revealed a partnership with Marathon Health to expand primary‑care access through Ambetter Health Solutions in selected Indiana and Missouri counties, a move aimed at broadening service reach. In addition, a Centene subsidiary, PA Health & Wellness, was named one of the top 17 Medicaid health plans in the United States by the National Committee for Quality Assurance for the second consecutive year, underscoring the company’s focus on quality managed care. These developments were reported to enhance operational efficiency, lower costs, and support a stronger financial outlook for the company.
LOW TARGET
$56 -19.1%
2 analysts
MEAN TARGET
$72 +3.7%
18 analysts
HIGH TARGET
$85 +22.8%
8 analysts
PRICE RANGE
$56.00 - $85.00
SB / B / H / S / SS
5/7/14/1/1
DAILYIQ EST.
$72.65 (+5.0%)
Sector
Healthcare
Industry
Healthcare Plans
Exchange
NYQ
Country
United States
Symbol
CNC
Description
Centene Corporation is a healthcare services provider focused on delivering care to government-sponsored and commercially insured individuals across the United States. The company's core business revolves around managing health benefits and offering a diverse range of programs through four primary segments: Medicaid, Medicare, Commercial, and Other. Centene's value proposition lies in its ability to serve a broad population, including those with limited access to traditional healthcare, by providing comprehensive coverage and services. Its offerings span various healthcare needs, from basic medical care to specialized services, including behavioral health and pharmacy benefits. Founded in 1984, the company operates through a network of providers, including physicians, hospitals, and other healthcare professionals, to deliver its services.
Bought (1Y)
0 shares
$0
Sold (1Y)
185,678 shares
$12.2M
COUGHLIN CHRISTOPHER J-
Award/Grant583 shares2026-09-30
EPPINGER FREDERICK H-
Award/Grant864 shares2026-09-30
Samuels Theodore R. II-
Award/Grant583 shares2026-09-30
TANJI KENNETH-
Award/Grant603 shares2026-09-30
Tyler Lauren M-
Award/Grant482 shares2026-09-30
62/ 100
Neutral / mixed
Overall: Neutral
✓Revenue growing year over year
✕Negative net margin
✓Positive operating cash flow
Gross Margin
8.1%
Net Margin
-3.8%
Revenue CAGR
26.1%
Current Ratio
1.10x
Debt / Equity
0.87x
Return on Equity
-33.4%
Earnings Summary
Centene Corporation is a diversified healthcare services provider that manages health benefits for government-sponsored and commercially insured individuals, operating through Medicaid, Medicare, Commercial, and Other segments. The company’s focus on broad population coverage places it firmly within the healthcare plans sector, where demand is largely driven by policy and demographic trends. In the most recent quarters, Centene posted a strong rebound: Q4 2024 EPS of $0.80 beat the $0.49 estimate, and Q1 2025 EPS of $2.90 surpassed the $2.52 estimate, while revenue grew from $40.8 billion to $46.6 billion, a 14.5% increase. The following quarter, however, saw a sharp reversal with Q2 2025 EPS of –$0.16 versus a $0.21 estimate and revenue rising modestly to $48.7 billion; Q3 2025 EPS rebounded to $0.50 against a –$0.16 estimate, and revenue reached $49.7 billion. Over the past year, the company has delivered consistent revenue growth, with Q1 2026 revenue of $49.94 billion up 6.5% from the prior year, and EPS of $3.37 beating the $2.13 estimate, followed by Q2 2026 EPS of $2.51 versus a $1.08 estimate and revenue of $53.58 billion, a 9.5% increase. Historically, Centene has shown a pattern of beating EPS estimates in the majority of recent quarters while maintaining steady revenue expansion, even when earnings dipped in Q2 2025. Recent news highlights a July 28 earnings surprise that pushed the stock to a 52‑week high, with guidance indicating a 135% EPS lift on modest revenue growth, underscoring investor confidence in profitability acceleration.

EPS

EstBeatMiss
$-1.93$-0.43$1.07$2.56$4.06Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$0.10 - -
Q2'26$1.08$2.51+132.6%
Q1'26$2.13$3.37+57.9%
Q4'25$-1.24$-1.19+3.7%
Q3'25$-0.16$0.50+404.3%
Q2'25$0.21$-0.16-177.3%

Revenue

EstBeatMiss
$46.6B$48.6B$50.6B$52.5B$54.5BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$47.6B - -
Q2'26$48.1B$53.6B+11.4%
Q1'26$47.6B$49.9B+5.0%
Q4'25$48.9B$49.7B+1.7%
Q3'25 - $49.7B -
Q2'25 - $48.7B -

Market Data

CNC Stock Snapshot

BULLISH92/100
$69.25+$0.25 (0.4%)
Market cap
32.91B
Day range
$68.83 – $69.25
News sentiment
63/100 · Bullish
Analyst target
$71.78 (+3.7%)
Consensus
Hold · 28 analysts
52-week range+119.8% off low · -1.1% from high
$31.50$70.04
Price $69.25 DailyIQ Est. $72.65

Centene Corporation screens well technically, with price sitting near its 52-week high. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.

Reverse DCF

What growth is priced into CNC?

CHEAP

At today's price, Centene Corporation needs to grow free cash flow about -20.0% a year for the next 10 years to justify its valuation at a 6.31% cost of capital. Over its actual history it has compounded free cash flow at 28.0% a year, so the market is asking for 48.0 percentage points below its own delivered rate. On that basis CNC looks priced below what its own growth record supports.

Implied FCF growth
-20.0% (capped)
Historical FCF CAGR
28.0%
Growth gap
-48.0 pts
Verdict
CHEAP
Discount rate (WACC)
6.31%
Beta
0.51

Behaviour On Record

What CNC's own history says about today's numbers

Realized volatility (21d)
30.9% 50th pct
Below its peak
-28.8%
vs 200-day average
+29.1%
Up days (1y)
53%

Centene Corporation is currently running 30.9% annualised volatility over the last 21 sessions. Measured against CNC's own 13 years of daily returns rather than a market-wide average, that is the 50th percentile — close to its own typical level, against a typical reading of 30.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

CNC is trading -28.8% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -28.3%, and the deepest was -61.7% in 2025. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +29.1% from its 200-day moving average. Against every other day in its history, that gap ranks at the 91st percentile — a wider gap than this stock usually carries. Over the past year CNC closed higher on 53% of sessions, and it is currently 4 sessions into a rising streak.

On October specifically: over 14 years of records, CNC finished the month higher 7 of 14 times, with a median return of +0.0% and an average of +2.6%. Its strongest month historically has been May at +5.4% on average, its weakest July at -3.2%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: CNC has opened more than 2% away from the prior close in 151 of 3,268 sessions (4.6% of the time), with the largest gaps running +7.6% and -10.5%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, CNC moved an average of 3.6% in the session after earnings, closing higher 1 of those 3 times, with a median move of -1.4% and a largest of +7.8%.

All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against CNC's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of CNC's sector?

Centene Corporation sits in the Health Care sector, currently ranked 5th of 12 GICS sectors by relative-strength rotation score (improving).

Sector rank
#5 of 12
Sector state
Improving
Sector rotation score
64

Options Market

What is the options market pricing for CNC?

CallsPuts

For Centene Corporation's nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.83), with at-the-money implied volatility around 25.0%. The options market is pricing roughly a ±1.9% move by that expiry — a range of about $61.06–$63.36.

Put/call ratio (2026-10-16)
0.83
ATM implied volatility
25.0%
Total open interest
20,335
Expected move by 2026-10-16
±1.9% ($61.06–$63.36)

Analyst Rating Changes

Are analysts turning bullish or bearish on CNC?

Argus Research most recently upgraded Centene Corporation to Buy on Aug 11, 2026 with a price target of $80. Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.

Latest action
Argus Research — Buy
90-day upgrades
1
90-day downgrades
0
Net rating momentum
+1
DateFirmActionRatingPrice target
Aug 11, 2026Argus ResearchUpgradeHold → Buy$80
Aug 4, 2026JP MorganMaintainedNeutral$60 → $67
Aug 3, 2026BernsteinMaintainedOutperform$68 → $79
Jul 29, 2026BarclaysMaintainedOverweight$75 → $80
Jul 29, 2026BairdMaintainedNeutral$46 → $66
Jul 14, 2026TD CowenMaintainedHold$47 → $65
Jul 14, 2026Truist SecuritiesMaintainedBuy$71 → $78
Jul 13, 2026Wells FargoMaintainedEqual-Weight$56 → $69
Jul 9, 2026RBC CapitalMaintainedSector Perform$70 → $71
Jul 7, 2026Cantor FitzgeraldMaintainedOverweight$60 → $75
Jun 23, 2026RBC CapitalInitiatedSector Perform$70
Jun 8, 2026MizuhoMaintainedNeutral$58 → $63

Peers & ETF holders

CNC peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

63/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
In October 2026, Centene Corporation announced a National Performance‑Based Gold Card Program to streamline prior authorization for over 160,000 providers, a plan to redeem $568.66 million of its 4.25% notes due 2027, and a primary‑care expansion through Ambetter Health Solutions and Marathon Health in Indiana and Missouri. The combination of a performance‑based authorization model, debt reduction, and expanded primary‑care access signals a focus on margin recovery and capital structure improvement. These moves are likely to influence investor perception of Centene’s operating efficiency and ability to support high‑quality care for government and Marketplace members.
What did this article say?
PA Health & Wellness, a Centene Corporation company, was named one of the top 17 Medicaid health plans in the United States by the National Committee for Quality Assurance for the second consecutive year. The recognition reflects the organization’s sustained commitment to quality and continuous improvement in delivering healthcare outcomes for Pennsylvanians. The award reinforces Centene’s reputation for high‑quality managed care services within its Medicaid portfolio.
What did this article say?
Centene announced a National Performance‑Based Gold Card Program set to launch in November 2026, aimed at simplifying prior authorization for outpatient services. The initiative will cover over 160,000 healthcare providers nationwide, reducing administrative burdens for qualifying services. The announcement prompted a 3.5% rise in shares, reflecting market recognition of the program’s potential to improve operational efficiency and patient access.
What did this article say?
Centene Corporation announced on October 13, 2026 that it would launch a National Performance-Based Gold Card Program in November 2026. The initiative targets more than 160,000 qualifying outpatient providers nationwide, aiming to simplify prior‑authorization reviews while upholding clinical and quality standards. Eligibility hinges on objective performance metrics such as approval history, documentation quality, and compliance with medical policy. The program is intended to reduce administrative burden and enhance accountability, with plans to expand to additional services and providers over time.
What did this article say?
Centene Corporation (CNC) experienced a sharp rebound, with its shares rising 73% over the past year. The company’s valuation has since approached fair value, suggesting that the recent upside has been largely priced in. Analysts view the current price as a hold, indicating that while the stock has recovered, there is limited upside potential in the near term. The positive momentum reflects improved fundamentals and market sentiment, but the lack of new catalysts tempers enthusiasm.
What did this article say?
Centene Corporation (CNC) is expected to report a fourth‑quarter profit of $0.07 per share, a decline of 86% from the $0.50 per share earned in the prior quarter. The company has historically exceeded earnings estimates, but the sharp projected drop signals a significant headwind for the upcoming quarter. Analysts anticipate the decline will be priced into the stock ahead of the earnings release on October 27. The forecast highlights potential challenges in Centene’s Medicaid and Medicare managed‑care operations. This negative outlook may prompt investors to reassess the company’s near‑term valuation.
What did this article say?
Centene Corporation (CNC) reported stronger Medicaid margins and Marketplace profitability, contributing to a 57% year‑to‑date share price increase. The company trades at a forward P/E of 12.34, below the industry average of 15.20, indicating a reasonable valuation relative to earnings outlook. Analysts note that the rapid improvement in operating results may support further upside, though sustainability remains a key consideration.
What did this article say?
Centene Corporation (CNC) announced a partnership with Marathon Health to provide eligible Ambetter members in select Indiana and Missouri counties with $0 primary care visits, lab services, and virtual care starting in the 2027 plan year. The collaboration aims to improve access to primary care for members through Ambetter Health Solutions and Marathon Health’s advanced primary care model. The move is expected to enhance member experience and potentially strengthen CNC’s Ambetter brand in the region.
What did this article say?
Centene Corporation (CNC) announced a new collaboration with Marathon Health to offer Ambetter members in select Indiana and Missouri counties $0 primary care visits, lab services, and virtual care beginning in 2027. The partnership, delivered through CHOICE Arrangements, expands CNC’s Ambetter Health Solutions network and enhances access to primary care for members. The deal is positioned to strengthen CNC’s competitive stance in the health insurance market.
What did this article say?
Centene Corporation (CNC) announced a strategic reduction of its Medicare Advantage (MA) footprint for 2027, withdrawing standard MA plans from 344 counties and exiting markets in Hawaii, Oklahoma, and Tennessee. The company will also trim its Wellcare unit’s plan lineup, concentrating on Special Needs Plans and dual-eligible members, who comprise about 40% of its MA enrollment. The move reflects ongoing medical‑cost pressures and a broader industry trend toward tighter geographic and benefit scopes. CNC’s decision signals a disciplined approach to managing profitability amid rising utilization and declining premium expectations.

Technical Analysis

Real-time indicators across multiple timeframes

92
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $14.09B combined position · 14 adding, 11 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
BlackRock, Inc.▲ Buy41,446,0468.72%$2.66B2026-08-07
Vanguard Group Inc▲ Buy56,978,75311.98%$2.34B2026-01-29
AQR Capital Management LLC▼ Sell28,678,7016.03%$1.84B2026-08-14
Geode Capital Management, LLC▲ Buy13,309,7292.80%$854.00M2026-08-12
Wellington Management Group LLP▲ Buy13,301,2152.80%$853.80M2026-08-14
Invesco Ltd.▲ Buy11,179,8442.35%$717.63M2026-08-14
Harris Associates L P▼ Sell11,124,6402.34%$714.09M2026-08-14
Morgan Stanley▲ Buy10,051,7002.11%$645.22M2026-08-13
Norges Bank▼ Sell7,651,7581.61%$491.17M2026-08-12
Goldman Sachs Group Inc▲ Buy6,359,1761.34%$408.20M2026-08-14
Two Sigma Investments, LP▼ Sell6,348,0381.34%$407.48M2026-08-14
D. E. Shaw & Co., Inc.▼ Sell5,213,4221.10%$334.65M2026-08-14
Northern Trust Corp▼ Sell4,930,6031.04%$316.50M2026-08-13
Bank of America Corp▲ Buy4,451,0540.94%$285.71M2026-08-14
Man Group plc▲ Buy2,795,1380.59%$179.42M2026-08-14
FMR LLC (Fidelity)▲ Buy2,628,7270.55%$168.74M2026-08-13
JPMorgan Chase & Co▲ Buy2,351,4480.49%$151.76M2026-08-12
Renaissance Technologies LLC▲ Buy2,192,4120.46%$140.73M2026-08-13
Glenview Capital Management, LLC▼ Sell1,886,0550.40%$121.07M2026-08-14
Millennium Management LLC▼ Sell1,590,8990.33%$102.12M2026-08-14
Capital World Investors▼ Sell1,339,2790.28%$85.97M2026-08-12
Marshall Wace, LLP▲ Buy1,272,6370.27%$81.69M2026-08-13
Citigroup Inc▲ Buy1,124,8690.24%$72.21M2026-08-03
Citadel Advisors LLC▼ Sell1,007,3260.21%$64.66M2026-09-02
Gotham Asset Management, LLC▼ Sell797,2360.17%$51.17M2026-08-14
Q2 2026 flow:18.25M sh bought ($1.17B)14.95M sh sold ($959.46M)net +3.30M sh (+$211.88M)
Congressional Trading Activity
20 disclosed trades · ~$523.0K est. traded value · 14 buys, 6 sells
MemberChamberStateTypeAmountTradedFiled
Tim MooreHouseNC14▼ Sell$100K - $250K2025-08-182025-09-03
Tim MooreHouseNC14▲ Buy$1K - $15K2025-08-082025-09-03
Julia LetlowHouseLA05▼ Sell$1K - $15K2025-08-082026-01-13
Tim MooreHouseNC14▲ Buy$15K - $50K2025-08-072025-09-03
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-08-052025-09-12
Tim MooreHouseNC14▲ Buy$15K - $50K2025-07-302025-08-05
Tim MooreHouseNC14▲ Buy$15K - $50K2025-07-292025-08-05
Tim MooreHouseNC14▲ Buy$1K - $15K2025-07-222025-08-05
Tim MooreHouseNC14▲ Buy$15K - $50K2025-07-212025-08-05
Tim MooreHouseNC14▲ Buy$15K - $50K2025-07-182025-08-05
Tim MooreHouseNC14▲ Buy$15K - $50K2025-07-142025-08-05
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-05-302025-06-06
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-05-152025-06-09
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-05-122025-06-22
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-04-292025-05-06
Julia LetlowHouseLA05▲ Buy$1K - $15K2025-04-142026-01-13
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-04-082025-05-08
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-03-312025-04-07
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-03-052025-04-11
Valerie HoyleHouseOR04▲ Buy$1K - $15K2024-10-292025-09-12